On the public citation graph

Efficacy and Safety Comparisons of Programmed Cell Death-1 vs Programmed Cell Death Ligand-1 Inhibitors in Patients with Cancer: A Systematic Review and Updated Meta-Analysis

https://doi.org/10.2139/ssrn.4658385
0 signed · 41 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2019.0393openalex-extracted
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
inferredcites →https://doi.org/10.1001/jamaoncol.2019.5367openalex-extracted
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
inferredcites →https://doi.org/10.1001/jamaoncol.2020.0237openalex-extracted
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1002/cncr.31043openalex-extracted
Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature
inferredcites →https://doi.org/10.1002/jrsm.1054openalex-extracted
Automating network meta‐analysis
inferredcites →https://doi.org/10.1002/jrsm.1167openalex-extracted
Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysis
inferredcites →https://doi.org/10.1016/j.annonc.2022.08.032openalex-extracted
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
inferredcites →https://doi.org/10.1016/j.ctrv.2021.102242openalex-extracted
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.intimp.2020.106852openalex-extracted
The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.iotech.2022.100164openalex-extracted
59MO Final analysis of AK105-302: A randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC
inferredcites →https://doi.org/10.1016/j.jtho.2016.10.007openalex-extracted
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
inferredcites →https://doi.org/10.1016/j.jtho.2018.04.025openalex-extracted
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
inferredcites →https://doi.org/10.1016/j.jtho.2022.07.072openalex-extracted
OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
inferredcites →https://doi.org/10.1016/j.jtho.2022.09.223openalex-extracted
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
inferredcites →https://doi.org/10.1016/j.jval.2011.04.002openalex-extracted
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
inferredcites →https://doi.org/10.1016/s0140-6736(15)60263-xopenalex-extracted
Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials
inferredcites →https://doi.org/10.1016/s0140-6736(17)31827-5openalex-extracted
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(18)32409-7openalex-extracted
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(22)01658-0openalex-extracted
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-extracted
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1910231openalex-extracted
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1917346openalex-extracted
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
inferredcites →https://doi.org/10.1056/nejmoa2106391openalex-extracted
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1073/pnas.0915174107openalex-extracted
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
inferredcites →https://doi.org/10.1093/annonc/mdy264openalex-extracted
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
inferredcites →https://doi.org/10.1093/annonc/mdz167openalex-extracted
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
inferredcites →https://doi.org/10.1126/science.aar4060openalex-extracted
Cancer immunotherapy using checkpoint blockade
inferredcites →https://doi.org/10.1136/bmj.326.7387.472openalex-extracted
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
inferredcites →https://doi.org/10.1136/ebmental-2019-300117openalex-extracted
How to perform a meta-analysis with R: a practical tutorial
inferredcites →https://doi.org/10.1186/s40425-018-0427-6openalex-extracted
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
inferredcites →https://doi.org/10.1200/jco.2014.59.4358openalex-extracted
Immune Checkpoint Blockade in Cancer Therapy
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.3065openalex-extracted
A meta-analysis to indirectly compare the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors using a Bayesian hierarchical model.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.9000openalex-extracted
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
inferredcites →https://doi.org/10.18637/jss.v106.i02openalex-extracted
netmeta : An R Package for Network Meta-Analysis Using Frequentist Methods
inferredcites →https://doi.org/10.2217/imt-2018-0110openalex-extracted
Programmed Cell Death-1/Programmed Cell Death Ligand-1 Checkpoint Inhibitors: Differences in Mechanism of Action
inferredcites →https://doi.org/10.3389/fimmu.2021.705096openalex-extracted
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
inferredcites →https://doi.org/10.3389/fimmu.2022.801909openalex-extracted
Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.3389/fphar.2017.00561openalex-extracted
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
inferredcites →https://doi.org/10.3390/curroncol29050247openalex-extracted
Immune Checkpoint Inhibitors in Cancer Therapy
inferredcites →https://doi.org/10.3390/jcm10163612openalex-extracted
Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.4081/oncol.2020.490openalex-extracted
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.